Codexis Inc. (CDXS) Stock Price Down 3.7%
Codexis Inc. (NASDAQ:CDXS) shares fell 3.7% during trading on Thursday . The stock traded as low as $4.15 and last traded at $4.16, with a volume of 108,408 shares. The stock had previously closed at $4.32.
Several research firms have recently commented on CDXS. Zacks Investment Research downgraded Codexis from a “hold” rating to a “sell” rating in a report on Wednesday, May 4th. HC Wainwright reiterated a “buy” rating on shares of Codexis in a report on Tuesday, May 10th.
The company has a 50-day moving average of $4.14 and a 200-day moving average of $3.80. The company’s market cap is $170.90 million.
Codexis (NASDAQ:CDXS) last announced its quarterly earnings results on Monday, May 9th. The company reported ($0.11) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.04. During the same period in the previous year, the business posted ($0.07) EPS. The business earned $8 million during the quarter, compared to the consensus estimate of $7.49 million. The firm’s revenue was up 17.6% on a year-over-year basis. Analysts expect that Codexis Inc. will post ($0.23) EPS for the current year.
In other news, major shareholder Ventures Fund Vii L.P. Vivo sold 80,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 4th. The shares were sold at an average price of $4.22, for a total transaction of $337,600.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.